Cargando…

Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain – results of a Delphi Panel

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a form of chronic fibrosing interstitial pneumonia characterized by progressive worsening of dyspnea and lung function, with a poor prognosis. The objective of this study was to determine treatment patterns, resource use and costs of managing Spanis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morell, Ferran, Esser, Dirk, Lim, Jonathan, Stowasser, Susanne, Villacampa, Alba, Nieves, Diana, Brosa, Max
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710031/ https://www.ncbi.nlm.nih.gov/pubmed/26758510 http://dx.doi.org/10.1186/s12890-016-0168-6

Ejemplares similares

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Parametric Time‐to‐Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis
por: Tang, Fei, et al.
Publicado: (2020)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Fracture Liaison Services Compared with Standard of Care in the Secondary Prevention of Fragility Fractures in Spain
por: Naranjo, Antonio, et al.
Publicado: (2022)

Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials
por: Costabel, Ulrich, et al.
Publicado: (2018)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

PIN154 QALY Losses Attributable to COVID-19 Pandemic in Spain
por: Hernando, V., et al.
Publicado: (2020)

A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study
por: Isla, Dolores, et al.
Publicado: (2022)

The association between asthma control, health care costs, and quality of life in France and Spain
por: Doz, Marianne, et al.
Publicado: (2013)

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value
por: Wuyts, Wim A., et al.
Publicado: (2016)

Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON
por: Song, Jin Woo, et al.
Publicado: (2019)

Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature
por: Kistler, Kristin D, et al.
Publicado: (2014)

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019
por: García-Goñi, Manuel, et al.
Publicado: (2021)

Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study
por: Cano-Jiménez, Esteban, et al.
Publicado: (2022)

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
por: Rinciog, C., et al.
Publicado: (2016)

Content Validity of CASA-Q Cough Domains and UCSD-SOBQ for Use in Patients with Idiopathic Pulmonary Fibrosis
por: Gries, Katharine, et al.
Publicado: (2013)

Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2019)

Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2022)

Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)
por: Rodríguez-Nieto, Maria Jesus, et al.
Publicado: (2023)

Cost of heart failure management in Turkey: results of a Delphi Panel
por: Aras, Dursun, et al.
Publicado: (2016)

Challenges for Clinical Drug Development in Pulmonary Fibrosis
por: White, Eric S., et al.
Publicado: (2022)

Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial
por: Noth, Imre, et al.
Publicado: (2021)

Idiopathic Pulmonary Fibrosis and Telomeres
por: Mulet, Alba, et al.
Publicado: (2022)

Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE)
por: Behr, Jürgen, et al.
Publicado: (2019)

The psychometric properties of the St George’s Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review
por: Swigris, Jeffrey J, et al.
Publicado: (2014)

Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry
por: Fernández-Fabrellas, Estrella, et al.
Publicado: (2019)

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension
por: Richeldi, Luca, et al.
Publicado: (2018)

The JAK2 pathway is activated in idiopathic pulmonary fibrosis
por: Milara, Javier, et al.
Publicado: (2018)

Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib
por: Rahaghi, Franck, et al.
Publicado: (2021)

Cost-of-disease of Heart Failure in Turkey: A Delphi Panel-based Analysis of Direct and Indirect Costs
por: Çavuşoğlu, Yüksel, et al.
Publicado: (2022)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Recommendations for the Use of Serious Games in Neurodegenerative Disorders: 2016 Delphi Panel
por: Manera, Valeria, et al.
Publicado: (2017)

Management of advanced ovarian cancer in Spain: an expert Delphi consensus
por: Redondo, Andres, et al.
Publicado: (2021)

Psychometric properties of the St George’s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials
por: Swigris, Jeffrey J, et al.
Publicado: (2018)

Drugs foresight 2020: a Delphi expert panel study
por: Lintonen, Tomi, et al.
Publicado: (2014)

Teleconsultations for mental health: Recommendations from a Delphi panel
por: Manera, Valeria, et al.
Publicado: (2023)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6il5n6hkt0jdje051gjljv38l3